表皮生长因子受体（EGFR）突变非小细胞肺癌（NSCLC）具有高度异质性，EGFR 突变类型、共突变状态、肿瘤负荷等均可能影响其靶向治疗效果。FLAURA2 研究最终总生存期（OS）数据显示，一线奥希替尼联合化疗可显著延长 EGFR 突变晚期 ...

《难治性肺癌中国专家共识》的发布，填补了我国该领域无统一诊疗规范的空白，通过 “定义 - 分类 - 分层治疗 - 新技术” ...

Scientists from A*STAR Institute of Molecular and Cell Biology (A*STAR IMCB) have identified why certain lung cancer cells ...

Scientists from A*STAR Institute of Molecular and Cell Biology (A*STAR IMCB) have identified why certain lung cancer cells become highly resistant to treatment after developing mutations in a key gene ...

SAN DIEGO--(BUSINESS WIRE)--Cellworks Group Inc., a leader in Personalized Therapy Decision Support and Precision Drug Development, today announced findings from a study using the Cellworks Platform ...

In a media release on Jan. 22, it was revealed that a group of scientists from the Agency for Science, Technology and ...

Real-world data demonstrate non-classical mutations are present in 20-30% of all patients with EGFRm NSCLC Emerging data show non-classical EGFR mutations can be co-expressed with the classical L858R ...

AI-powered model predicts EGFR mutations from H&E-stained slides, demonstrating robust performance across diverse clinical settings and helping overcome barriers to molecular testing in NSCLC EGFR ...

CNW/ - AstraZeneca Canada is pleased to announce that Tagrisso® (osimertinib) and Calquence® (acalabrutinib tablets) are now ...